Uganda: NDA Issues Statement on Conduct of Clinical Trials during COVID-19

July 20, 2021

The Uganda National Drug Authority (NDA) issued a statement on June 28, 2021, to sponsors and principal investigators (PIs) regarding the conduct of clinical trials during the COVID-19 lockdown. The statement notes the following:

  • Clinical trial reviews will continue to be done remotely
  • Researchers are asked to submit applications electronically to
  • Researchers are encouraged to limit administrative submissions that have no bearing on participant safety or trial integrity
  • Principal investigators and sponsors are responsible for continuing to follow good clinical practice principles

For details on all of Uganda's clinical research regulatory requirements, view the Uganda country profile on ClinRegs.